Three US Food and Drug Administration–approved therapies for chronic GVHD
Robert Zeiser, Stephanie J. Lee
Abstract
Chronic graft-versus-host disease (cGVHD) is a major immunologic complication of allogeneic hematopoietic cell transplantation. cGVHD involves multiple organs, reduces quality of life, and often requires prolonged therapy with glucocorticoids, causing severe side effects. After 4 decades of testing multiple therapeutic approaches, ibrutinib, belumosudil, and ruxolitinib were US Food and Drug Administration approved for cGVHD in the last 4 years. Here we put a spotlight on their mechanisms of action, studies that led to approval, and their future role in cGVHD.
Topics & Concepts
MedicineIbrutinibRuxolitinibFood and drug administrationGraft-versus-host diseaseDrugTransplantationDiseaseImmunologyIntensive care medicineInternal medicineChronic lymphocytic leukemiaPharmacologyLeukemiaBone marrowMyelofibrosisChronic Lymphocytic Leukemia ResearchHematopoietic Stem Cell TransplantationAcute Lymphoblastic Leukemia research